Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
-
Zhongguo Zhong Yao Za Zhi · Sep 2013
Review Meta Analysis[Systematic review of xiyanping injection for hand foot mouth disease].
To assess the efficacy and safety of Xiyanping injection for hand foot mouth disease. All Clinical studies of Xiyanping injection for hand foot mouth disease were searched from Cochrane library, Medline, EMbase, CBM, CNKI, Wanfang and VIP. Selection of trials for inclusion, data extraction, assessment of methodological quality were completed by two independent screening. ⋯ The systematic review suggests that Xiyanping injection in the combination with conventional treatment may improve the efficacy of the treatment of hand foot mouth disease. However, as all of the included trials were published in Chinese and of poor quality, we cannot draw a sure conclusion. More rigorous trials with high quality are required.
-
Zhongguo Zhong Yao Za Zhi · Sep 2013
[Based on propensity score methods analysis of outcomes of parenterally administered shuxuetong in treatment of cerebral infarction].
Hospital information system (HIS) data from 18 hospitals was analyzed. 107 723 cases were divided into two groups, those that received Shuxuetong and those that did not. Patients, 18 to 80 years old, suffering from cerebral infarction, whose treatment outcome was clear were selected. ⋯ The three methods of comparison indicated that the use of Shuxuetong significantly increased cure rates compared to the control group. Therefore, based on existing data, for the treatment of cerebral infarction, the outcomes are more effective when combination therapy including Shuxuetong is used.
-
Zhongguo Zhong Yao Za Zhi · Sep 2013
[Analysis of adverse reactions and pharmacovigilance research to parenterally administered shuxuening].
Parenterally administered Shuxuening is a commonly used Chinese medicine. There is a need to understand the characteristics of adverse drug reactions (ADRs) to it. 9 601 ADR cases reports were collected from the national adverse drug reaction monitoring center reported between January, 2005 and December, 2012. These included 326 serious ADR cases, accounting for 3.93% of the total. ⋯ Through the use of proportional reporting ratio (PRR) and Bayesian confidence propagation neural network (BCPNN) and propensity score applying generalized boosted models (GBM) to control for 17 confounding factors, analysis of the 10 kinds of ADRs found that for the ADR signals of dizziness, palpitations, phlebitis, and vomiting, BCPNN found that dizziness and phlebitis were early warning signals. This research found that in the 60-89 age group, higher dosages of parenterally administered Shuxuening gave rise to more phlebitis. This study provides important information for parenterally administered Shuxuening research, and guidance for its risk management.
-
Zhongguo Zhong Yao Za Zhi · Sep 2013
[Spontaneous reporting system data analysis of parenterally administered Shenmai].
Spontaneous reporting system (SRS) datais currently an important source of monitoring and finding ADRs signals throughout the world. This method can promptly and effectively discover ADR signals, thus preventing and avoiding ADRs effectively. Parenterally administered Shenmai has the functions of benefiting vital energy, nourishing Yin and generating body fluids, and activating the pulse. ⋯ Early warning signs of an ADR are, a feeling of suffocation (difficulty exhaling), anaphylactoid reactions and flushing. Furthermore, relevant relationships between the different factors is analysed by association rules (AR). It is found that there is a close relationship between past history of ADRs, a family history of ADRs and itching.
-
Zhongguo Zhong Yao Za Zhi · Sep 2013
[Treatment outcomes of parenterally administered dengzhan xixin for treatment of cerebral infaction based on real world hospital injection system data].
Cerebral infarction is one of the indications for parenterally administered Dengzhan Xixin. This study aims to analyze treatment outcomes in patients with cerebral infarction of parenterally administered Dengzhan Xixin, in the real world. Data from 20 national hospitals' hospital injection system (HIS) databases were collected. 1 008 cases of parenterally administered Dengzhan Xixin for the treatment of cerebral infarction were compared with 1 504 cases who did not receive Dengzhan Xixin who acted as the control group. ⋯ This study concludes that parenterally administered Dengzhan Xixin can reduce the mortality of cerebral infarction patients based on existing data. However,there are many known and unknown confounders in retrospectively analysis, and the propensity score can only control for known confounding factors. Therefore, these findings should be considered as a reference for treating cerebral infarction.